HRP20161490T1 - Spojevi kinazolina - Google Patents
Spojevi kinazolina Download PDFInfo
- Publication number
- HRP20161490T1 HRP20161490T1 HRP20161490TT HRP20161490T HRP20161490T1 HR P20161490 T1 HRP20161490 T1 HR P20161490T1 HR P20161490T T HRP20161490T T HR P20161490TT HR P20161490 T HRP20161490 T HR P20161490T HR P20161490 T1 HRP20161490 T1 HR P20161490T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- pharmaceutically acceptable
- acceptable salt
- compound
- corresponding pharmaceutically
- Prior art date
Links
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 8
- CFOTUIGPYHMGMD-UHFFFAOYSA-N 1H-pyrrolo[3,4-b]pyrrole-5-carboxamide Chemical compound N1C=2C(C=C1)=CN(C=2)C(=O)N CFOTUIGPYHMGMD-UHFFFAOYSA-N 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 102000001301 EGF receptor Human genes 0.000 claims 2
- 108060006698 EGF receptor Proteins 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 2
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- FSXCKIBROURMFT-VGSWGCGISA-N (3ar,6ar)-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]-1-methyl-2,3,3a,4,6,6a-hexahydropyrrolo[2,3-c]pyrrole-5-carboxamide Chemical compound C=12C=C(NC(=O)N3C[C@@H]4N(C)CC[C@@H]4C3)C(OC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 FSXCKIBROURMFT-VGSWGCGISA-N 0.000 claims 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Claims (10)
1. Spoj (3aR,6aR)-N-(4-(3-etinilfenilamino)-7-metoksikinazolin-6-il)-1-metil-heksahidro pirolo[3,4-b]-pirol-5(1H)-karboksamid, ili najmanje jedna odgovarajuća farmaceutski prihvatljiva sol.
2. Farmaceutski pripravak koji sadrži najmanje jedan farmaceutski prihvatljiv nosač i spoj (3aR,6aR)-N-(4-(3-etinilfenilamino)-7-metoksikinazolin-6-il)-1-metil-heksahidro pirolo[3,4-b]pirol-5(1H)-karboksamid, i/ili najmanje jednu odgovarajuću farmaceutski prihvatljivu sol.
3. Spoj (3aR,6aR)-N-(4-(3-etinilfenilamino)-7-metoksikinazolin-6-il)-1-metil-heksahidro pirolo[3,4-b]-pirol-5(1H)-karboksamid, i/ili najmanje jedna odgovarajuća farmaceutski prihvatljiva sol za upotrebu u liječenju karcinoma.
4. Spoj i/ili najmanje jedna odgovarajuća farmaceutski prihvatljiva sol za upotrebu prema patentnom zahtjevu 3, naznačeno time da je karcinom odabran od sljedećih: karcinom pluća, karcinom glave i vrata, karcinom kolorektuma, karcinom ždrijela, epidermoidni karcinom i karcinom pankreasa.
5. Spoj i/ili najmanje jedna odgovarajuća farmaceutski prihvatljiva sol za upotrebu prema patentnom zahtjevu 4, naznačeno time da karcinom jest karcinom ne-male stanice pluća.
6. Spoj i/ili najmanje jedna odgovarajuća farmaceuski prihvatljiva sol za upotrebu prema patentnom zahtjevu 3 u kombinaciji s drugim protu-karcinomskim sredstvom koje nije (3aR,6aR)-N-(4-(3-etinil-fenilamino)-7-metoksikinazolin-6-il)-1-metil-heksahidro pirolo[3,4-b]pirol-5(1H)-karboksamid i/ili najmanje jedna odgovarajuća farmaceutski prihvatljiva sol.
7. Metoda in vitro inhibicije prekomjerne ekspresije i/ili prekomjerne aktivnosti receptora faktora rasta epiderme dovođenjem u doticaj spoja i/ili najmanje jedne odgovarajuće farmaceutski prihvatljive soli prema patentnom zahtjevu 1 s receptorom faktora rasta epiderme.
8. Upotreba spoja i/ili najmanje jedne odgovarajuće farmaceutski prihvatljive soli prema patentnom zahtjevu 1 za pripravu lijeka za liječenje karcinoma.
9. Upotreba prema patentnom zahtjevu 8, naznačena time da je karcinom odabran od sljedećih: karcinom pluća, karcinom glave i vrata, karcinom kolorektuma, karcinom ždrijela, epidermoidni karcinom i karcinom pankreasa.
10. Upotreba prema patentnom zahtjevu 9, naznačena time da karcinom jest karcinom ne-male stanice pluća.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2010/074792 WO2012000182A1 (en) | 2010-06-30 | 2010-06-30 | Quinazoline compounds |
| EP11800101.5A EP2590966B1 (en) | 2010-06-30 | 2011-05-25 | Quinazoline compounds |
| PCT/CN2011/074637 WO2012000356A1 (en) | 2010-06-30 | 2011-05-25 | Quinazoline compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161490T1 true HRP20161490T1 (hr) | 2016-12-16 |
Family
ID=45401313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161490TT HRP20161490T1 (hr) | 2010-06-30 | 2016-11-11 | Spojevi kinazolina |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9168253B2 (hr) |
| EP (1) | EP2590966B1 (hr) |
| JP (1) | JP5736452B2 (hr) |
| KR (1) | KR101480481B1 (hr) |
| AU (1) | AU2011274183B2 (hr) |
| BR (1) | BR112012033344B1 (hr) |
| CA (1) | CA2801814C (hr) |
| DK (1) | DK2590966T3 (hr) |
| ES (1) | ES2604929T3 (hr) |
| HK (1) | HK1179954A1 (hr) |
| HR (1) | HRP20161490T1 (hr) |
| HU (1) | HUE029801T2 (hr) |
| LT (1) | LT2590966T (hr) |
| MX (1) | MX2012015047A (hr) |
| MY (1) | MY172201A (hr) |
| PL (1) | PL2590966T3 (hr) |
| PT (1) | PT2590966T (hr) |
| RS (1) | RS55470B1 (hr) |
| RU (1) | RU2530887C2 (hr) |
| SG (1) | SG186410A1 (hr) |
| SI (1) | SI2590966T1 (hr) |
| WO (2) | WO2012000182A1 (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR092289A1 (es) | 2011-11-14 | 2015-04-15 | Sunshine Lake Pharma Co Ltd | Derivados de aminoquinazolina y sus sales y metodos de uso |
| WO2018099451A1 (zh) * | 2016-12-01 | 2018-06-07 | 和记黄埔医药（上海）有限公司 | 化合物的晶型 |
| KR101957464B1 (ko) | 2018-10-18 | 2019-03-12 | 대흥전력기술 주식회사 | 활선 상태에서 지상기기의 점검 및 누유 보수방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4444762A (en) | 1980-04-04 | 1984-04-24 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
| GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| CN101619043B (zh) * | 2008-06-30 | 2013-06-05 | 和记黄埔医药（上海）有限公司 | 喹唑啉衍生物及其医药用途 |
| US8426430B2 (en) * | 2008-06-30 | 2013-04-23 | Hutchison Medipharma Enterprises Limited | Quinazoline derivatives |
-
2010
- 2010-06-30 WO PCT/CN2010/074792 patent/WO2012000182A1/en active Application Filing
-
2011
- 2011-05-25 SG SG2012093779A patent/SG186410A1/en unknown
- 2011-05-25 CA CA2801814A patent/CA2801814C/en not_active Expired - Fee Related
- 2011-05-25 LT LTEP11800101.5T patent/LT2590966T/lt unknown
- 2011-05-25 EP EP11800101.5A patent/EP2590966B1/en active Active
- 2011-05-25 RU RU2012153174/04A patent/RU2530887C2/ru active
- 2011-05-25 US US13/807,460 patent/US9168253B2/en not_active Expired - Fee Related
- 2011-05-25 MX MX2012015047A patent/MX2012015047A/es active IP Right Grant
- 2011-05-25 RS RS20160973A patent/RS55470B1/sr unknown
- 2011-05-25 ES ES11800101.5T patent/ES2604929T3/es active Active
- 2011-05-25 HU HUE11800101A patent/HUE029801T2/en unknown
- 2011-05-25 DK DK11800101.5T patent/DK2590966T3/en active
- 2011-05-25 PL PL11800101T patent/PL2590966T3/pl unknown
- 2011-05-25 AU AU2011274183A patent/AU2011274183B2/en not_active Ceased
- 2011-05-25 MY MYPI2012005682A patent/MY172201A/en unknown
- 2011-05-25 BR BR112012033344-5A patent/BR112012033344B1/pt not_active IP Right Cessation
- 2011-05-25 PT PT118001015T patent/PT2590966T/pt unknown
- 2011-05-25 WO PCT/CN2011/074637 patent/WO2012000356A1/en active Application Filing
- 2011-05-25 JP JP2013516973A patent/JP5736452B2/ja not_active Expired - Fee Related
- 2011-05-25 KR KR20137001865A patent/KR101480481B1/ko active IP Right Grant
- 2011-05-25 SI SI201131012A patent/SI2590966T1/sl unknown
-
2013
- 2013-06-18 HK HK13107098.1A patent/HK1179954A1/xx not_active IP Right Cessation
-
2016
- 2016-11-11 HR HRP20161490TT patent/HRP20161490T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1179954A1 (en) | 2013-10-11 |
| JP2013529653A (ja) | 2013-07-22 |
| CA2801814C (en) | 2015-04-07 |
| RU2530887C2 (ru) | 2014-10-20 |
| SI2590966T1 (sl) | 2016-12-30 |
| LT2590966T (lt) | 2016-11-25 |
| US20130172373A1 (en) | 2013-07-04 |
| RS55470B1 (sr) | 2017-04-28 |
| WO2012000356A1 (en) | 2012-01-05 |
| BR112012033344A2 (pt) | 2016-11-29 |
| KR101480481B1 (ko) | 2015-01-09 |
| EP2590966A1 (en) | 2013-05-15 |
| SG186410A1 (en) | 2013-01-30 |
| CA2801814A1 (en) | 2012-01-05 |
| EP2590966A4 (en) | 2014-01-15 |
| MX2012015047A (es) | 2013-02-07 |
| KR20130031358A (ko) | 2013-03-28 |
| RU2012153174A (ru) | 2014-08-10 |
| AU2011274183B2 (en) | 2013-09-26 |
| BR112012033344B1 (pt) | 2020-12-15 |
| DK2590966T3 (en) | 2016-12-19 |
| HUE029801T2 (en) | 2017-04-28 |
| EP2590966B1 (en) | 2016-08-31 |
| AU2011274183A1 (en) | 2013-01-10 |
| WO2012000182A1 (en) | 2012-01-05 |
| US9168253B2 (en) | 2015-10-27 |
| PT2590966T (pt) | 2016-11-29 |
| ES2604929T3 (es) | 2017-03-10 |
| JP5736452B2 (ja) | 2015-06-17 |
| MY172201A (en) | 2019-11-15 |
| PL2590966T3 (pl) | 2017-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200624T1 (hr) | Derivati 2-(2,4,5-supstituiranog-anilino)pirimidina kao modulatori egfr korisni za liječenje raka | |
| UA111604C2 (uk) | ЗАМІЩЕНІ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНОВІ СОЛІ | |
| NZ629442A (en) | Heterocyclyl compounds as mek inhibitors | |
| TN2011000244A1 (en) | Organic compounds | |
| NZ710636A (en) | Heterocyclic compounds and uses thereof | |
| NZ601754A (en) | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 | |
| RS53898B1 (en) | QUINAZOLINE-4 (3H) -ONE DERIVATIVES USED AS PI3 KINASE INHIBITORS | |
| IL217044A (en) | Derivatives of h5- [1,3] thiazolo [2,3- a] pyrimidine-5-oz or their salts acceptable in pharmacy, pharmaceuticals containing them, a method of pi3k kinase activity control and use thereof | |
| EA201300620A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА И ИМИДАЗО[4,5-b]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ JAK | |
| PH12014502865A1 (en) | Selective pi3k delta inhibitors | |
| MX2012002875A (es) | Derivados de 6-amino-quinazolina o 3-ciano-quinolina, metodos de preparacion y usos farmaceuticos de los mismos. | |
| MD4735B1 (ro) | Derivaţi ai pirolo[2,3-d]pirimidinei ca inhibitori de Kinaze Janus-asociate (JAK) | |
| MY170326A (en) | Imidazo [1,2-b] pyridazine derivativea as kinase inhibitors | |
| AP2012006631A0 (en) | 6-Cycloalkyl-1, 5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A inhibitors | |
| MX2010008638A (es) | Furo-[3,2-c]piridinas y tieno[3,2-c]piridinas. | |
| HRP20221304T1 (hr) | Kombinacija koja sadrži inhibitor mek i inhibitor b-raf | |
| ZA201108544B (en) | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | |
| EA201200618A1 (ru) | Производные хроменона с антиопухолевой активностью | |
| EA201201191A1 (ru) | 4-[циклоалкилокси(гетеро)ариламино]тиено[2,3-d]пиримидины, обладающие ингибирующей активностью по отношению к mnkl/mnk2, предназначенные для фармацевтических композиций | |
| HRP20161490T1 (hr) | Spojevi kinazolina | |
| WO2009021169A3 (en) | (7h-pyrr0l0 [2, 3-d] pyrimidin-4-yl) -piperazines as kinase inhibitors for the treatment of cancer and inflammation | |
| HRP20161522T1 (hr) | Derivati 6.7-dialkoksi kinazolina korisni za liječenje poremećaja povezanih s rakom | |
| BR112014018795A2 (pt) | derivados de 1h-pirrolo[2,3-b]piridina e seu uso como inibidores de cinase | |
| WO2007084875A3 (en) | Spiro compounds and methods of use | |
| EP2549874A4 (en) | SUBSTITUTED IMIDAZOLE [1,2-B] PYRIDAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS |